Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Resverlogix to Host BETonMACE Webcast and Conference Call

GlobeNewswire September 26, 2019

Toronto Stock Exchange Introduces the TSX30

Canada NewsWire September 26, 2019

Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association's Scientific Sessions 2019

GlobeNewswire September 23, 2019

Resverlogix Provides Update on BETonMACE Phase 3 Trial

GlobeNewswire September 16, 2019

Resverlogix Announces Annual and Special Meeting of Shareholders

GlobeNewswire August 22, 2019

Zenith Announces Annual and Special Meeting of Shareholders

GlobeNewswire August 22, 2019

Resverlogix to Present at the European Society of Cardiology's ESC Congress 2019

GlobeNewswire August 14, 2019

Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

GlobeNewswire August 6, 2019

Resverlogix Announces Loan Reduction and Extension

GlobeNewswire August 2, 2019

Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics

GlobeNewswire July 15, 2019

Resverlogix's BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits

GlobeNewswire July 8, 2019

Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

GlobeNewswire June 27, 2019

Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial

GlobeNewswire June 12, 2019

Resverlogix Announces Participation at Leading, International Scientific Conferences

GlobeNewswire June 10, 2019

Resverlogix Announces Closing of $15 Million Offering

GlobeNewswire June 7, 2019

IIROC Trade Resumption - RVX

Canada NewsWire May 15, 2019

Resverlogix Announces Pricing of Unit Offering

GlobeNewswire May 15, 2019

IIROC Trading Halt - RVX

Canada NewsWire May 15, 2019

Resverlogix Announces Proposed Offering of Units

GlobeNewswire May 14, 2019

Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)

GlobeNewswire May 6, 2019